When the word “fluorine” surfaces in public discourse, it often evokes concern about per- and polyfluoroalkyl substances—PFAS—widely dubbed “forever chemicals” due to their extreme environmental persistence and growing regulatory scrutiny. Yet this apprehension has spilled over into clinical practice, prompting questions: Do fluorinated pharmaceuticals—long staples across antimicrobial, antifungal, antidiabetic, and oncologic therapy—pose similar health risks? And do their known adverse effects stem from the presence of fluorine itself?
Fluorine remains one of the most strategically valuable elements in modern medicinal chemistry. Approximately 20–30% of FDA-approved small-molecule drugs contain at least one fluorine atom—a deliberate design choice that enhances metabolic stability, membrane permeability, and target binding affinity. Clinically relevant examples include fluoroquinolone antibiotics (e.g., levofloxacin, moxifloxacin), antifungals (e.g., fluconazole), dipeptidyl peptidase-4 inhibitors (e.g., sitagliptin), and several targeted anticancer agents.
Crucially, these therapeutic fluorinated compounds are chemically and toxicologically distinct from PFAS. PFAS—such as perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS)—are synthetic surfactants engineered for thermal, chemical, and water resistance. They persist indefinitely in soil, water, and human tissue and are found in consumer products ranging from nonstick cookware and waterproof textiles to food packaging and certain medical devices—including some ophthalmic formulations. In contrast, fluorinated drugs feature covalently bound, metabolically labile C–F bonds embedded within complex organic scaffolds; they are designed for pharmacokinetic predictability and eventual biotransformation—not environmental accumulation.
A pivotal 2025 observational study led by researchers at the University of Birmingham analyzed real-world adverse drug reaction (ADR) data across more than 1,200 fluorinated medications. The team found no statistically significant correlation between ADR incidence and either the number of fluorine atoms per molecule or the specific fluorinated moiety (e.g., trifluoroethyl vs. fluorophenyl). Instead, adverse events clustered predictably by pharmacologic class—neuropsychiatric symptoms with fluoroquinolones, hypoglycemia with certain DPP-4 inhibitors, or hepatotoxicity with select antifungals—underscoring that toxicity arises from the drug’s overall mechanism of action, not fluorine per se.
Meanwhile, PFAS represent a separate and well-documented public health challenge. As highlighted in a 2024 review published in *Ecological Indicators*, PFAS exhibit multi-organ toxicity—including neurotoxicity, immunosuppression, endocrine disruption, hepatorenal injury, pulmonary inflammation, and developmental impairment. Epidemiologic evidence links chronic low-level exposure to increased risks of thyroid dysfunction, reduced vaccine response, diminished fertility, chronic kidney disease, and elevated incidence of renal and testicular cancers. Environmental monitoring reveals elevated PFAS concentrations near fluoropolymer manufacturing sites and in municipal water supplies downstream of industrial discharge zones.
Emerging concerns extend to next-generation fluorinated compounds. A 2026 study in *Environment International* investigated perfluorohexyloctane (F6H8), a candidate for ophthalmic and dermatologic applications. Using primary human hepatocyte models, investigators detected a stable, structurally analogous metabolite—perfluorohexyloctanoic acid—that mirrors classic PFAS behavior, including resistance to enzymatic degradation and intracellular accumulation. While F6H8 is not currently classified as a regulated PFAS, its metabolic profile raises legitimate questions about long-term bioaccumulation potential and warrants proactive toxicokinetic evaluation before broader clinical adoption.
Clinical vigilance remains essential—but appropriately targeted. Regulatory agencies, including China’s National Medical Products Administration (NMPA), have issued multiple safety communications—most notably Alert No. 58 (2013)—emphasizing fluoroquinolone-associated risks such as tendon rupture, peripheral neuropathy, and aortic dissection. These warnings reflect robust pharmacovigilance data and are implemented via updated prescribing information and risk mitigation strategies—not because of fluorine, but because of the compound’s off-target interactions with collagen metabolism and mitochondrial function.
In summary, conflating fluorinated therapeutics with environmental PFAS undermines evidence-based medicine. Fluorine’s role in drug design is intentional, well-characterized, and pharmacologically beneficial. Its presence does not confer “forever chemical” properties. Conversely, PFAS exposure—whether occupational, environmental, or iatrogenic—demands rigorous surveillance and precautionary stewardship. The appropriate stance is neither alarmist nor dismissive: clinicians should prescribe fluorinated drugs according to established indications and safety protocols, while remaining attentive to evolving science on fluorinated industrial compounds—especially those entering biomedical applications without full toxicologic profiling.